1. Home
  2. SGHT vs RCS Comparison

SGHT vs RCS Comparison

Compare SGHT & RCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sight Sciences Inc.

SGHT

Sight Sciences Inc.

HOLD

Current Price

$5.02

Market Cap

235.0M

Sector

Health Care

ML Signal

HOLD

Logo PIMCO Strategic Income Fund Inc.

RCS

PIMCO Strategic Income Fund Inc.

HOLD

Current Price

$5.50

Market Cap

251.8M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
SGHT
RCS
Founded
2011
1994
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Investment Managers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
235.0M
251.8M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
SGHT
RCS
Price
$5.02
$5.50
Analyst Decision
Buy
Analyst Count
7
0
Target Price
$9.08
N/A
AVG Volume (30 Days)
126.9K
141.7K
Earning Date
05-06-2026
01-01-0001
Dividend Yield
N/A
10.12%
EPS Growth
28.16
N/A
EPS
N/A
N/A
Revenue
$77,363,000.00
N/A
Revenue This Year
$11.67
N/A
Revenue Next Year
$10.39
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.11
$5.09
52 Week High
$9.24
$8.00

Technical Indicators

Market Signals
Indicator
SGHT
RCS
Relative Strength Index (RSI) 56.42 51.96
Support Level $4.76 $5.41
Resistance Level $5.25 $5.68
Average True Range (ATR) 0.29 0.10
MACD 0.02 0.00
Stochastic Oscillator 73.73 47.79

Price Performance

Historical Comparison
SGHT
RCS

About SGHT Sight Sciences Inc.

Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The company operates through two segments: Interventional Glaucoma, which generates the majority of revenue and includes the OMNI Surgical System family of products and the SION Surgical Instrument used in minimally invasive glaucoma surgery to reduce intraocular pressure in adult patients with open-angle glaucoma; and Interventional Dry Eye, which includes the TearCare System, an interventional device designed to melt and facilitate the removal of meibomian gland obstructions and restore gland functionality in adult patients with evaporative dry eye disease.

About RCS PIMCO Strategic Income Fund Inc.

PIMCO Strategic Income Fund, Inc. operates as a closed-end management investment company. Its primary investment objective is to generate a level of income that is higher than that generated by high-quality, intermediate-term U.S. debt securities. The Fund also seeks capital appreciation to the extent consistent with the objective.

Share on Social Networks: